<DOC>
	<DOCNO>NCT00649961</DOCNO>
	<brief_summary>Preterm baby risk brain injury . Melatonin , naturally occur hormone , may reduce risk . The unborn baby receive melatonin mother follow premature delivery maybe period prolong melatonin deficiency . This deficiency may harmful study suggest melatonin important protecting brain reduce risk brain injury preterm birth . The purpose study find ideal dose melatonin give preterm baby . We intend study total 24 baby less 31 week gestation le 7 day old .</brief_summary>
	<brief_title>Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study</brief_title>
	<detailed_description>PURPOSE OF THE STUDY AND OBJECTIVES The overall purpose investigate whether melatonin , achieve adult maternal peak blood level preterm infant , reduce brain injury white matter disease define specialised magnetic resonance imaging ( MRI ) term . Before test hypothesis clinical trial , dose melatonin require achieve desire concentration preterm infant need determine . This data use clinical double blind randomised trial separate application make ethic committee . The principal research objective study determine dose require achieve physiological melatonin blood level preterm infant similar mother . Secondary objective define pharmacokinetic profile melatonin preterm infant . STUDY DESIGN AND METHODOLOGY The propose clinical trial single dose , open label , dose escalation pharmacokinetic study preterm infant less 31weeks gestation achieve adult peak blood concentration melatonin ( 200-250 pmol/L ) . The trial multi centre study base Neonatal Intensive Care Units UK . TREATMENT A single intravenous infusion melatonin give infant 6 hour first 7 day life . The start dose 0.1 microgram/kg/hr increase decrease incrementally subsequent group infant desire melatonin concentration achieve . DURATION The duration treatment 6 hour . INVESTIGATIONS Pharmacokinetic assessment perform blood urine sample collect 2 hourly various timepoints . STATISTICAL ANALYSIS Pharmacokinetic assessment do use appropriate software .</detailed_description>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<mesh_term>Neuroprotective Agents</mesh_term>
	<criteria>Infants bear less 31 week gestation le 7 day old , parental consent participation include study . Those major congenital malformation , cystic periventricular leucomalacia ( cPVL ) haemorrhagic parenchymal infarct ( HPI ) cranial ultrasonography prior enrolment exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>23 Weeks</minimum_age>
	<maximum_age>31 Weeks</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Premature Birth</keyword>
	<keyword>Brain injury</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>Melatonin</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>